WO2009121036A3 - Substituted aryl pyrimidinone derivatives - Google Patents

Substituted aryl pyrimidinone derivatives Download PDF

Info

Publication number
WO2009121036A3
WO2009121036A3 PCT/US2009/038692 US2009038692W WO2009121036A3 WO 2009121036 A3 WO2009121036 A3 WO 2009121036A3 US 2009038692 W US2009038692 W US 2009038692W WO 2009121036 A3 WO2009121036 A3 WO 2009121036A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted aryl
pyrimidinone derivatives
ligands
compounds
methods
Prior art date
Application number
PCT/US2009/038692
Other languages
French (fr)
Other versions
WO2009121036A2 (en
Inventor
Charles A. Blum
Bertrand L. Chenard
Isamir Martinez
Xiaozhang Zheng
Original Assignee
Neurogen Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corporation filed Critical Neurogen Corporation
Publication of WO2009121036A2 publication Critical patent/WO2009121036A2/en
Publication of WO2009121036A3 publication Critical patent/WO2009121036A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Substituted aryl pyrimidinone derivatives are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.
PCT/US2009/038692 2008-03-27 2009-03-27 Substituted aryl pyrimidinone derivatives WO2009121036A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3981908P 2008-03-27 2008-03-27
US61/039,819 2008-03-27

Publications (2)

Publication Number Publication Date
WO2009121036A2 WO2009121036A2 (en) 2009-10-01
WO2009121036A3 true WO2009121036A3 (en) 2009-12-17

Family

ID=41114808

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/038692 WO2009121036A2 (en) 2008-03-27 2009-03-27 Substituted aryl pyrimidinone derivatives

Country Status (1)

Country Link
WO (1) WO2009121036A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003656B2 (en) 2006-08-23 2011-08-23 Neurogen Corporation 2-phenoxy pyrimidinone analogues
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076946A2 (en) * 2001-03-26 2002-10-03 Novartis Ag Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
WO2006122200A1 (en) * 2005-05-11 2006-11-16 Merck Sharp & Dohme Limited 2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076946A2 (en) * 2001-03-26 2002-10-03 Novartis Ag Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
WO2006122200A1 (en) * 2005-05-11 2006-11-16 Merck Sharp & Dohme Limited 2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1)

Also Published As

Publication number Publication date
WO2009121036A2 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
WO2009012482A3 (en) 5-membered heterocyclic amides and related compounds
WO2008066789A3 (en) Heteroaryl amide derivatives
WO2006078992A3 (en) Heteroaryl substituted piperazinyl-pyridine analogues
MY148461A (en) Heteroaryl amide analogues as p2x7 antagonists
WO2006026135A3 (en) Substituted biaryl piperazinyl-pyridine analogues
WO2006076646A3 (en) Heteroaryl substituted quinolin-4-ylamine analogues
WO2007101007A3 (en) Aryl sulfonyl heterocycles
WO2006081388A3 (en) Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues
WO2008024433A3 (en) Haloalkyl-substituted pyrimidinone derivatives
WO2008024438A3 (en) 2-phenoxy pyrimidinone analogues
WO2007140383A3 (en) Spirocyclic sulfonamides and related compounds
WO2005084401A3 (en) Aryl substituted purine analogues
WO2006042289A3 (en) Substituted biaryl quinolin-4-ylamine analogues
WO2005007648A3 (en) Biaryl piperazinyl-pyridine analogues
TW200716594A (en) Substituted heteroaryl CB1 antagonists
WO2008066664A3 (en) Cis-cyclohexyl substituted pyrimidinone derivatives
WO2008016811A3 (en) Aminopiperidines and realted compounds
WO2004055004A8 (en) Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
WO2005007652A3 (en) Substituted quinolin-4-ylamine analogues
WO2008033739A3 (en) Benzimidazole carboxamide derivatives
WO2005023807A3 (en) 4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists
WO2005084368A3 (en) Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues
WO2006071538A3 (en) Substituted biaryl analogues
WO2005086968A3 (en) Substituted 5,12-diaza-benzoanthracene analogues
WO2009121036A3 (en) Substituted aryl pyrimidinone derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09726419

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09726419

Country of ref document: EP

Kind code of ref document: A2